Treatment non-adherence is a general challenge and a complex problem. It is a key factor that impacts the ‘real-life’ effectivenessof topical treatments for chronic disorders, such as psoriasis. Here, we provide our expert opinion on the real-lifeeffectiveness of topical psoriasis treatment, using the fixed combination gel (Daivobet gel; calcipotriol plus betamethasonedipropionate) as a case study. The fixed combination gel is a first-line topical treatment for mild-to-moderate psoriasis,developed to be the gold-standard therapy for psoriasis patients. This fixed combination gel is an effective and well-toleratedtopical psoriasis treatment that themajority of our patients prefer to the ointment formulation.We assessed our real-lifeexperience and considered any gaps between daily practice and clinical trials data.Werecommend a multifaceted approachto improve real-life effectiveness and bridge the gap between investigational trials and treatment reality and propose the followingrecommendations: (1) educate primary healthcare providers on how to effectivelymanage topical psoriasis treatmentand the patients who use the treatment; (2) educate the patient on why treatment needs to bemaintained, even when symptomsimprove; and (3) provide a supportive environment that will not allow the patient to feel abandoned. A patient-centricapproach may improve adherence, which will lead to patients receiving more effective treatment for psoriasis.
Expert recommendations: the use of the fixed combination calcipotriol and betamethasone dipropionate gel for the topical treatment of psoriasis
GIROLOMONI, Giampiero;
2014-01-01
Abstract
Treatment non-adherence is a general challenge and a complex problem. It is a key factor that impacts the ‘real-life’ effectivenessof topical treatments for chronic disorders, such as psoriasis. Here, we provide our expert opinion on the real-lifeeffectiveness of topical psoriasis treatment, using the fixed combination gel (Daivobet gel; calcipotriol plus betamethasonedipropionate) as a case study. The fixed combination gel is a first-line topical treatment for mild-to-moderate psoriasis,developed to be the gold-standard therapy for psoriasis patients. This fixed combination gel is an effective and well-toleratedtopical psoriasis treatment that themajority of our patients prefer to the ointment formulation.We assessed our real-lifeexperience and considered any gaps between daily practice and clinical trials data.Werecommend a multifaceted approachto improve real-life effectiveness and bridge the gap between investigational trials and treatment reality and propose the followingrecommendations: (1) educate primary healthcare providers on how to effectivelymanage topical psoriasis treatmentand the patients who use the treatment; (2) educate the patient on why treatment needs to bemaintained, even when symptomsimprove; and (3) provide a supportive environment that will not allow the patient to feel abandoned. A patient-centricapproach may improve adherence, which will lead to patients receiving more effective treatment for psoriasis.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
